

Viral Vector Manufacturing - Global Market Outlook (2017-2026)

<https://marketpublishers.com/r/V3DBB54CC69EN.html>

Date: February 2019

Pages: 168

Price: US\$ 4,150.00 (Single User License)

ID: V3DBB54CC69EN

Abstracts

According to Statistics MRC, the Global Viral Vector Manufacturing Market is accounted for \$227.63 million in 2017 and is expected to reach \$1013 million by 2026 growing at a CAGR of 18.0% during the forecast period. The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches are some of the factors propelling the market growth. However, the excessive cost of gene therapies and possible mutagenesis impede the market.

Viral Vector Manufacturing comprises the generation of these vectors, which then have to be purified in order to meet the quality attributes required for further use as gene delivery systems. Viral or non-viral vector methods are used the inefficient transfer of the therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.

On the basis of application, Gene Therapy segment holds the significant growth during the forecast period due to the availability of effective viral vector gene therapies for rare diseases & cancers, ongoing research activities on viral vector gene therapies.

Based on geography, North America holds the major market share during the forecast period owing to rise in research activities, a large number of regenerative medicine companies, increase in the prevalence of target diseases and availability of funds.

Some of the key players profiled in the Viral Vector Manufacturing Market include Spark Therapeutics, Uniqure, Kaneka Eurogentec, Regenxbio, Finvector Vision Therapies, Novasep, Massbiologics, Merck KGaA, Cobra Biologics, Fujifilm Holdings Corporation,

Lonza, Brammer Bio, Oxford Biomedica and Thermo Fisher Scientific Inc.

Types Covered:

Adenoviral Vectors

Retroviral Vectors

Adeno-Associated Viral Vectors

Pox Virus

Cytomegalovirus

Other Types

Diseases Covered:

Human Disease

Veterinary Disease

Applications Covered:

Vaccinology

Gene Therapy

End Users Covered:

Research Institutes

Pharmaceutical and Biopharmaceutical Companies

Other End Users

Regions Covered:**North America**

US

Canada

Mexico

Europe

Germany

UK

Italy

France

Spain

Rest of Europe

Asia Pacific

Japan

China

India

Australia

New Zealand

South Korea

Rest of Asia Pacific

South America

Argentina

Brazil

Chile

Rest of South America

Middle East & Africa

Saudi Arabia

UAE

Qatar

South Africa

Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country level segments

Strategic recommendations for the new entrants

Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

- 2.1 Abstract
- 2.2 Stake Holders
- 2.3 Research Scope
- 2.4 Research Methodology
 - 2.4.1 Data Mining
 - 2.4.2 Data Analysis
 - 2.4.3 Data Validation
 - 2.4.4 Research Approach
- 2.5 Research Sources
 - 2.5.1 Primary Research Sources
 - 2.5.2 Secondary Research Sources
 - 2.5.3 Assumptions

3 MARKET TREND ANALYSIS

- 3.1 Introduction
- 3.2 Drivers
- 3.3 Restraints
- 3.4 Opportunities
- 3.5 Threats
- 3.6 Application Analysis
- 3.7 End User Analysis
- 3.8 Emerging Markets
- 3.9 Futuristic Market Scenario

4 PORTERS FIVE FORCE ANALYSIS

- 4.1 Bargaining power of suppliers
- 4.2 Bargaining power of buyers
- 4.3 Threat of substitutes
- 4.4 Threat of new entrants
- 4.5 Competitive rivalry

5 GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY TYPE

- 5.1 Introduction
- 5.2 Adenoviral Vectors
- 5.3 Retroviral Vectors
 - 5.3.1 Gamma-Retroviral Vectors
 - 5.3.2 Lentiviral Vectors
- 5.4 Adeno-Associated Viral Vectors
- 5.5 Pox Virus
- 5.6 Cytomegalovirus
- 5.7 Other Types
 - 5.7.1 Herpes Simplex Virus Vectors

6 GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY DISEASE

- 6.1 Introduction
- 6.2 Human Disease
 - 6.2.1 Infectious Diseases
 - 6.2.1.1 Influenza
 - 6.2.1.2 Malaria
 - 6.2.1.3 Hepatitis
 - 6.2.2 Genetic Disorders
 - 6.2.2.1 Human Immunodeficiency Virus (HIV)
 - 6.2.2.2 Tuberculosis
 - 6.2.3 Cancer
 - 6.2.4 Other Human Diseases
- 6.3 Veterinary Disease
 - 6.3.1 Avian Influenza
 - 6.3.2 Marek's Disease
 - 6.3.3 Infectious Bronchitis
 - 6.3.4 Peste des Petits Ruminants (PPR) Disease
 - 6.3.5 Other Veterinary Diseases
 - 6.3.5.1 Rabies
 - 6.3.5.2 Fibromuscular Dysplasia (FMD)
 - 6.3.5.3 Swine Influenza
 - 6.3.5.4 Equine Influenza
 - 6.3.5.5 Newcastle Disease

7 GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY APPLICATION

- 7.1 Introduction
- 7.2 Vaccinology
 - 7.2.1 Multivalent Vaccines
 - 7.2.2 Multipathogen Vaccines
- 7.3 Gene Therapy

8 GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY END USER

- 8.1 Introduction
- 8.2 Research Institutes
- 8.3 Pharmaceutical and Biopharmaceutical Companies
- 8.4 Other End Users

9 GLOBAL VIRAL VECTOR MANUFACTURING MARKET, BY GEOGRAPHY

- 9.1 Introduction
- 9.2 North America
 - 9.2.1 US
 - 9.2.2 Canada
 - 9.2.3 Mexico
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.2 UK
 - 9.3.3 Italy
 - 9.3.4 France
 - 9.3.5 Spain
 - 9.3.6 Rest of Europe
- 9.4 Asia Pacific
 - 9.4.1 Japan
 - 9.4.2 China
 - 9.4.3 India
 - 9.4.4 Australia
 - 9.4.5 New Zealand
 - 9.4.6 South Korea
 - 9.4.7 Rest of Asia Pacific
- 9.5 South America
 - 9.5.1 Argentina
 - 9.5.2 Brazil

- 9.5.3 Chile
- 9.5.4 Rest of South America
- 9.6 Middle East & Africa
 - 9.6.1 Saudi Arabia
 - 9.6.2 UAE
 - 9.6.3 Qatar
 - 9.6.4 South Africa
 - 9.6.5 Rest of Middle East & Africa

10 KEY DEVELOPMENTS

- 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
- 10.2 Acquisitions & Mergers
- 10.3 New Product Launch
- 10.4 Expansions
- 10.5 Other Key Strategies

11 COMPANY PROFILING

- 11.1 Spark Therapeutics
- 11.2 Uniquore
- 11.3 Kaneka Eurogentec
- 11.4 Regenxbio
- 11.5 Finvector Vision Therapies
- 11.6 Novasep
- 11.7 Massbiologics
- 11.8 Merck KGaA
- 11.9 Cobra Biologics
- 11.10 Fujifilm Holdings Corporation
- 11.11 Lonza
- 11.12 Brammer Bio
- 11.13 Oxford Biomedica
- 11.14 Thermo Fisher Scientific Inc.

List Of Tables

LIST OF TABLES

- 1 Global Viral Vector Manufacturing Market Outlook, By Region (2016-2026) (\$MN)
- 2 Global Viral Vector Manufacturing Market Outlook, By Type (2016-2026) (\$MN)
- 3 Global Viral Vector Manufacturing Market Outlook, By Adenoviral Vectors (2016-2026) (\$MN)
- 4 Global Viral Vector Manufacturing Market Outlook, By Retroviral Vectors (2016-2026) (\$MN)
- 5 Global Viral Vector Manufacturing Market Outlook, By Gamma-Retroviral Vectors (2016-2026) (\$MN)
- 6 Global Viral Vector Manufacturing Market Outlook, By Lentiviral Vectors (2016-2026) (\$MN)
- 7 Global Viral Vector Manufacturing Market Outlook, By Adeno-Associated Viral Vectors (2016-2026) (\$MN)
- 8 Global Viral Vector Manufacturing Market Outlook, By Pox Virus (2016-2026) (\$MN)
- 9 Global Viral Vector Manufacturing Market Outlook, By Cytomegalovirus (2016-2026) (\$MN)
- 10 Global Viral Vector Manufacturing Market Outlook, By Other Types (2016-2026) (\$MN)
- 11 Global Viral Vector Manufacturing Market Outlook, By Herpes Simplex Virus Vectors (2016-2026) (\$MN)
- 12 Global Viral Vector Manufacturing Market Outlook, By Disease (2016-2026) (\$MN)
- 13 Global Viral Vector Manufacturing Market Outlook, By Human Disease (2016-2026) (\$MN)
- 14 Global Viral Vector Manufacturing Market Outlook, By Infectious Diseases (2016-2026) (\$MN)
- 15 Global Viral Vector Manufacturing Market Outlook, By Genetic Disorders (2016-2026) (\$MN)
- 16 Global Viral Vector Manufacturing Market Outlook, By Cancer (2016-2026) (\$MN)
- 17 Global Viral Vector Manufacturing Market Outlook, By Other Human Diseases (2016-2026) (\$MN)
- 18 Global Viral Vector Manufacturing Market Outlook, By Veterinary Disease (2016-2026) (\$MN)
- 19 Global Viral Vector Manufacturing Market Outlook, By Avian Influenza (2016-2026) (\$MN)
- 20 Global Viral Vector Manufacturing Market Outlook, By Marek's Disease (2016-2026) (\$MN)

- 21 Global Viral Vector Manufacturing Market Outlook, By Infectious Bronchitis (2016-2026) (\$MN)
- 22 Global Viral Vector Manufacturing Market Outlook, By Peste des Petits Ruminants (PPR) Disease (2016-2026) (\$MN)
- 23 Global Viral Vector Manufacturing Market Outlook, By Other Veterinary Diseases (2016-2026) (\$MN)
- 24 Global Viral Vector Manufacturing Market Outlook, By Application (2016-2026) (\$MN)
- 25 Global Viral Vector Manufacturing Market Outlook, By Vaccinology (2016-2026) (\$MN)
- 26 Global Viral Vector Manufacturing Market Outlook, By Multivalent Vaccines (2016-2026) (\$MN)
- 27 Global Viral Vector Manufacturing Market Outlook, By Multipathogen Vaccines (2016-2026) (\$MN)
- 28 Global Viral Vector Manufacturing Market Outlook, By Gene Therapy (2016-2026) (\$MN)
- 29 Global Viral Vector Manufacturing Market Outlook, By End User (2016-2026) (\$MN)
- 30 Global Viral Vector Manufacturing Market Outlook, By Research Institutes (2016-2026) (\$MN)
- 31 Global Viral Vector Manufacturing Market Outlook, By Pharmaceutical and Biopharmaceutical Companies (2016-2026) (\$MN)
- 32 Global Viral Vector Manufacturing Market Outlook, By Other End Users (2016-2026) (\$MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

I would like to order

Product name: Viral Vector Manufacturing - Global Market Outlook (2017-2026)

Product link: <https://marketpublishers.com/r/V3DBB54CC69EN.html>

Price: US\$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V3DBB54CC69EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970